Optimizing Pneumococcal Prevention: Clinical Updates and Implementation Strategies For Pharmacy-Based Vaccination Services
Rupal Mansukhani, PharmD, FAPhA, NCNTT, discusses how pneumococcal disease presents differently across age groups; identifies high-risk populations, including adults older than 50 years and immunocompromised patients; compares the 5 FDA-approved pneumococcal vaccines with emphasis on newer conjugate options like PCV20 and PCV21; and provides guidance for pharmacists on vaccine recommendations, addressing patient concerns and implementing effective follow-up systems to improve vaccination uptake and completion rates.
EP. 1: Clinical Presentation of Pneumococcal Disease in Children and Adults
June 30th 2025An expert discusses how pneumococcal disease presents differently across age groups, with children primarily experiencing ear infections, whereas adults face more serious, invasive complications such as bacteremia and meningitis, though vaccination efforts have significantly reduced overall incidence rates.
Watch
EP. 2: Vulnerable Patients and the Burden of Pneumococcal Disease
June 30th 2025An expert discusses how pharmacists can identify high-risk patients for pneumococcal disease by reviewing medication profiles for immunosuppressants and using electronic medical record vaccine tracking tools, while emphasizing that vulnerable populations face higher morbidity, mortality, and hospitalization rates compared with healthy individuals.
Watch
